GO
Loading...

Merck & Co Inc

More

  • European shares close higher after Draghi speaks Monday, 17 Nov 2014 | 11:44 AM ET

    European shares closed higher after ECB President Mario Draghi reiterated that he was willing to do more to stimulate the euro zone economy.

  • Stock futures decline as Japan slides into recession Monday, 17 Nov 2014 | 9:17 AM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks looked set to decline at the open on Monday, with global shares hit by the news that Japan had unexpectedly slipped into recession.

  • US stocks seen lower after Japan enters recession Monday, 17 Nov 2014 | 6:03 AM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks looked set to decline at the open on Monday, with global shares hit by the news that Japan had unexpectedly slipped into recession.

  • German Merck, Pfizer in immunotherapy deal Monday, 17 Nov 2014 | 5:47 AM ET

    Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.

  • Nov 16- Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results. Georgina Long, an associate professor at the Melanoma Institute Australia who helped lead...

  • Stocks little moved, with S&P 500 and Dow at records Tuesday, 11 Nov 2014 | 4:16 PM ET
    Trader on the floor of the New York Stock Exchange.

    U.S. stocks ended near highs on Tuesday, with the Dow and S&P each edging up to a record close.

  • Nov 11- AbbVie Inc said its experimental drug that treats genotype 4 hepatitis C showed high response rates in a mid-stage study in patients who have been considered difficult to treat. AbbVie said on Tuesday 100 percent of the patients who were given the drug and had failed previous treatment showed high response rates at 12 weeks after the treatment.

  • Lighting Round: This one is a strong buy Monday, 10 Nov 2014 | 7:09 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Arrowhead CEO: We feel 'great' about the drug Monday, 10 Nov 2014 | 6:55 PM ET

    Arrowhead Research Chief Executive Chris Anzalone contends the company's hepatitis B therapy, ARC-520, has potential.

  • Merck: 4-week hepatitis C treatment too short Monday, 10 Nov 2014 | 6:52 PM ET
    Employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Merck hoped to trump Gilead's hepatitis C treatment with its own shorter therapy, but early results show the four-week regimen may not be successful.

  • Cramer's military salute: Long-term investing keys Monday, 10 Nov 2014 | 6:10 PM ET

    Jim Cramer focuses on three long-term investment themes specialized for veterans and active-duty soldiers.

  • S&P, Dow again rise to record closes amid earnings Monday, 10 Nov 2014 | 4:21 PM ET
    A trader works on the floor of the New York Stock Exchange, Oct. 15, 2014.

    Stocks edged higher on Monday as investors tracked corporate results as the earnings season starts to wind down.

  • Midday movers: Merck & Co., GoPro, Blackberry & more Monday, 10 Nov 2014 | 12:57 PM ET

    Some of Monday's midday movers:

  • Businesses fear water scarcity risks: Survey Friday, 7 Nov 2014 | 12:34 PM ET
    The dried cracked bed of the Qaraoun artificial lake is seen in West Bekaa, Lebanon, Sept. 19, 2014.

    Businesses say their growth plans could be seriously threatened by a lack of water availability. And the the threat could become real within a year.

  • Stocks to watch ahead of liver disease conference Friday, 7 Nov 2014 | 11:58 AM ET
    A scientist working at the Gilead Sciences laboratory in Foster City, Calif.

    Researchers, companies and Wall Street are gathering to gain a sense of bringing potentially multibillion dollar drugs to market.

  • LONDON, Nov 6- AstraZeneca, which saw off a $118 billion bid from Pfizer in May, said quarterly results showed its standalone strength, while recent U.S. tax changes removed much of the case for a new takeover attempt. Chief Executive Pascal Soriot, who has fought hard to prove AstraZeneca does not need the kind of mega-merger offered by Pfizer, said he would use the...

  • LONDON, Nov 6- AstraZeneca raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of generic copies of its Nexium drug in the United States kept cash flowing from the heartburn and ulcer pill. Britain's second biggest drugmaker, which saw off a $118 billion takeover bid from Pfizer in May, now expects revenue to grow in low...

  • LONDON, Nov 6- AstraZeneca raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of Nexium generics in the United States kept cash flowing from the heartburn and ulcer pill. Britain's second biggest drugmaker, which saw off a $118 billion takeover approach from Pfizer in May, now expects revenue to grow slightly this...

  • Gabelli exec's 'crown jewel' picks for US investing Wednesday, 5 Nov 2014 | 2:22 PM ET

    Global pain will mean U.S. gain at least in terms of stock market investing, according to a strongly bullish analysis from Mario Gabelli's team.

  • Stocks end mostly lower as oil drops, ballots cast Tuesday, 4 Nov 2014 | 4:20 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks fell Tuesday as the price of oil slid to a three-year low.